Clinical trial · Observational
The Effect of the COVID-19 Pandemic on Primary Bladder Cancer Presentations
NCT04900259CI-TRIAL-00054309completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, investigators aim to reveal how the COVID-19 pandemic process affects primary bladder cancer presentations, tumor stages and degrees, the time elapsed between diagnosis and intervention, tumor recurrence and progression, which are oncological results.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Covid19 | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| COVID-19 pandemic | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- COVID-19 Bladder Cancer
- description
- Patients diagnosed with primary bladder cancer in the COVID-19 period
- interventionNames
- Behavioral: COVID-19 pandemic
- label
- PreCOVID-19 Bladder Cancer
- description
- Patients diagnosed with primary bladder cancer in the preCOVID-19 period
- interventionNames
- Behavioral: COVID-19 pandemic
Primary outcomes (1)
- measure
- Rate of tumor stages
- timeFrame
- 2 months
- description
- Rate of tumor stages in patients who diagnosed with bladder cancer
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Primary bladder cancer Exclusion Criteria: * Previous history of urinary tract tumor * Chronic kidney disease
References
Publications (3)
- BACKGROUNDHeldwein FL, Loeb S, Wroclawski ML, Sridhar AN, Carneiro A, Lima FS, Teoh JY. A Systematic Review on Guidelines and Recommendations for Urology Standard of Care During the COVID-19 Pandemic. Eur Urol Focus. 2020 Sep 15;6(5):1070-1085. doi: 10.1016/j.euf.2020.05.020. Epub 2020 Jun 5. PMID 32532703
- BACKGROUNDEsperto F, Pang KH, Albisinni S, Papalia R, Scarpa RM. Bladder Cancer at the time of COVID-19 Outbreak. Int Braz J Urol. 2020 Jul;46(suppl.1):62-68. doi: 10.1590/S1677-5538.IBJU.2020.S107. PMID 32549074
- BACKGROUNDWallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N, Gillessen S, Bossi A, Roupret M, Powles T, Necchi A, Catto JWF, Klaassen Z. Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. Eur Urol. 2020 Jul;78(1):29-42. doi: 10.1016/j.eururo.2020.04.063. Epub 2020 May 3. PMID 32414626